Newsroom

menschlichen Lungengewebsschnitten
News
In May 2020, the international consortium iCAIR® started a research project aimed at developing therapeutics against SARS-CoV-2. The Helmholtz Centre for Infection Research (HZI), which joined forces with the consortium's core team last year, is also closely involved in this project. The HZI researchers under the leadership of Prof. Ulrich Kalinke have expanded the iCAIR® outstanding talent pool: they boast a successful track record in antiviral drug research, in particular against human pathogenic RNA viruses, and have compound libraries as well as test models and primary virus isolates. In addition, a team from Fraunhofer ITMP led by Prof. Carsten Claussen and Dr. Ole Pless is on board as a temporary project partner. The iCAIR® research team already can report promising results, which were presented by iCAIR® coordinator Prof. Armin Braun and others at Fraunhofer ITEM's virtual workshop "Models of Lung Disease" in January.
08.04.2021
Rasterelektronenmikroskopische Aufnahme von Mycobacterium tuberculosis
News
Every year, about 10 million people become infected with tuberculosis and 1.4 million die from it. This makes tuberculosis not only one of the most widespread infectious diseases, but also the deadliest. Similar to malaria or HIV, the prevalence of tuberculosis is strongly dependent on social factors; it is considered a classic disease of the poor. In addition to a lack of medical care, other problems hinder the containment of tuberculosis, such as antibiotic resistance and undesirable drug-drug interactions.
24.03.2021
Illustration
News
The bacterium Pseudomonas aeruginosa is among the most common causes of pneumonia and poses a major challenge to hospitals worldwide. The treatment of infections with Pseudomonas aeruginosa is usually challenging because the bacterium forms so-called biofilms, which protect it from drugs. Dr Martin Empting and his team, in collaboration with several groups at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), have now developed an innovative method to disrupt the formation of these biofilms and thus facilitate the treatment of infections with Pseudomonas aeruginosa. The researchers have published their findings in the journal Advanced Science.
19.03.2021
Grafik Myelom-Zellen mit BCMA-Expression
News
Therapeutically modified white blood cells hold great potential in the treatment of multiple myeloma, a malignant cancer of the bone marrow. However, they can lead to serious resistance in treated patients. In close cooperation, medical doctors and scientists from the University Hospital and the Helmholtz Institute for RNA-based Infection Research in Würzburg have now investigated the causes of this previously unexplained phenomenon. In the process, they uncovered a crucial resistance mechanism. The results were just published in the journal Nature Medicine.
11.03.2021
Modell Antikörper
News
An international research team of the Technische Universität Braunschweig and the Helmholtz Centre for Infection Research (HZI), led by the Department of Biotechnology of the TU Braunschweig, has reported on the development of special antibodies against SARS-CoV-2 in the journal Nature Communications. These antibodies prevent the viruses from entering host cells and were isolated from an antibody gene library that had already been produced from immune cells of healthy donors before the pandemic. The study shows how, in the future, active substances to previously unknown, emerging viruses can be produced very quickly without patient material.
11.03.2021
News
The CoVerage tool analyses the lineage dynamics of SARS-CoV-2 strains, i.e. determines how successfully which virus strain spreads. The web resource uses input from the Gisaid genome database. Gisaid is an international initiative that aims to make research data rapidly available to the public. Scientists from all over the world contribute genome sequences of viruses such as H1N1, influenza or SARS-CoV-2 to the database, thus providing a broad overview of mutations and their genetic differences. However, to predict the spread potential of these mutations, a simple count of incidences is not sufficient.
04.03.2021

HZI in the media

before and we just didn’t notice?” asks Fabian Leendertz, director of the Helmholtz Institute for One Health. He points out that wildlife

25.06.2025
|
Resurgence

... Samonellen liegen unter Schwarzlicht im Labor des Helmholtz-Zentrums in Braunschweig. Foto: Peter Steffen/dpa ...

23.06.2025
|
Kurier

Slevogt from the MHH and the Helmholtz Centre for Infection Research (“Helmholtz-Zentrum für Infektionsforschung“; HZI). An application for

23.06.2025
|
Trading View

... der Universität des Saarlandes , des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS) und internationalen Teams ...

19.06.2025
|
CHIP

Forschende am Helmholtz-Zentrum für Infektionsforschung in Braunschweig (Niedersachsen) arbeiten an einer neuer Impfstoff-Technologie, die

18.06.2025
|
17:30 SAT.1 REGIONAL

... machen

 

Die Studie der Wissenschaftler des Helmholtz-Zentrums für Infektionsforschung (HZI) in Braunschweig will daher vor ...

18.06.2025
|
Cityblick 24

including Dr. Max Kellner and Prof.‌ Josef Penninger of the⁢ Helmholtz Center for Infection Research (HZI), explored this ‌resilience.They

17.06.2025
|
Newsdirectory3

the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Chair of Microbiology of the Julius-Maximilians-Universität Würzburg

17.06.2025
|
Phys.org

Instituts für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für Infektionsforschung (HZI) ...

17.06.2025
|
DeutschesGesundheitsPortal

Register now for the HZI-Newsletter

and stay up to date!

CAPTCHA image for SPAM prevention If you can't read the word, click here.